1.4% 41.1% 0% 25% 50% 75% Sham Zenkuda Zenkuda in Diabetic Retinopathy: Established superiority in ≥2-step improvement in DRSS in GLOW1 and GLOW2 Superiority 3.3% 62.5% Sham Zenkuda Proportion of patients with ≥2-Step improvement in Diabetic Retinopathy Severity Score (DRSS) from Baseline to Week 48 GLOW1 p<0.0001 GLOW2 p<0.0001 6-month Durability GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130); Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Note: Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates Phase 3 GLOW1 GLOW2 100% of patients on 6-month dosing at Year 1 28